Vitrolife is going through a period with softer organic growth in the 3-6% which compares with a mor...
48% org growth, sales +4% vs cons, EBIT -16% on one-off costs Reiterates mid-term and long-term guid...
Solid Service revenue growth of 30%
Redeye endorses today’s news that Herantis has presented positive phase Ia data with HER-096, and th...
Redeye comments on SenzaGen’s Q3 2023 sales update.
Redeye comments on the recently announced cost-cutting program, which is expected to yield an annual...
Finnair’s Q3 EBIT was impressive even if higher fuel prices already had some adverse impact.
Innofactor posted good Q3 results, in line with our estimates.
Sales +5% y-o-y, -6% vs. ABGSCe on lower delivery sales 11% adj.
Redeye provides a brief comment on Sprint Bioscience’s Q3 report.
Net sales SEK 183m, 10% vs ABGSCe, 13% vs Factset cons.
Decelerating growth in Q3 due to the weakened market Ework is prioritising profitability over growth...
Redeye comments on Sleep Cycle's Q3 2023 report, which was in line with our sales estimates but stro...
Net sales was above consensus (Refinitiv) in Q3. Clean operating profit margin was also better than ...
Redeye sees a Q3 report with solid ACV numbers, but with sales and EBIT hurt by lower Deliveries in ...
Sales +9% vs. ABGSCe, EBIT +75% vs. ABGSCe Organic growth of -10%, better than ABGSCe -20% Order boo...
Redeye retains its positive view on Lagercrantz following a Q2 report with strong margins.
Aktiekursen i Starbreeze har straffats rejält efter att spelaraktiviteten på PC-plattformen Steam ha...
Redeye gives a short comment on Ependion’s Q3 2023 report, which came in close to our forecasts, not...
Redeye comments on Stillfront's Q3-results which came in below our forecast, mainly owing to Albion ...
